19 June 2025
19 June 2025
NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.
At BIO 2025, FDA Commissioner Dr Marty Makary tried to allay industry concerns about recent cuts and outlined his agenda for the future.
The FDA approval was based on the outcomes from Phase III PURPOSE I and II trials.
Penny Dash shared her views during a fireside discussion at HLTH Europe in Amsterdam.
Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding dries up.
The investment will be used to propel the company's lead candidate DT-101 into Phase II trials for MDD.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
